[Skip to Navigation]
August 1996

Intraocular Pressure-Raising Potential of 1.0% Rimexolone in Patients Responding to Corticosteroids

Author Affiliations

From Boston University School of Medicine, Boston, Mass (Dr Leibowitz); School of Optometry, University of Alabama, Birmingham (Dr Bartlett); Eye Institute of Indiana, Indianapolis (Dr Rich); Eye-Tech, Memphis, Tenn (Dr McQuirter); Houston Eye Associates, Houston, Tex (Dr Stewart); and Anheuser-Busch Eye Institute, St Louis, Mo (Dr Assil). None of the authors has any commercial, proprietary, or financial interest in any of the products described in this article. Dr Leibowitz has occasionally served as a paid consultant to Alcon Laboratories Inc (Fort Worth, Tex).

Arch Ophthalmol. 1996;114(8):933-937. doi:10.1001/archopht.1996.01100140141005

Objective:  To compare the intraocular pressure (IOP) elevating potential of 1.0% rimexolone and 0.1% fluorometholone alcohol ophthalmic suspensions in patients known to have responded to corticosteroids.

Design:  In a double-masked, randomized, single-eye, crossover protocol, corticosteroid responsiveness initially was verified in 40 asymptomatic known steroid responders by challenge with either 0.1% dexamethasone sodium phosphate or 1.0% prednisolone acetate for up to 6 weeks. After a 1-month medication washout, subjects randomly received either rimexolone or fluorometholone for 6 weeks. Medications were again discontinued for 1 month, and subjects then received the alternate drug for 6 weeks.

Results:  There was no significant difference between rimexolone and fluorometholone in the number of subjects demonstrating a 10-mm Hg increase in IOP or in the mean number of weeks required to achieve a 10-mm Hg response. Responses occurred in significantly more subjects receiving dexamethasone sodium phosphate (P=.001) or prednisolone acetate (P<.001) and in a significantly shorter interval than in subjects receiving rimexolone.

Conclusions:  Rimexolone has a low IOP-elevating potential, comparable to that of fluorometholone and less than that of dexamethasone sodium phosphate and prednisolone acetate.

Add or change institution